Loading
The Leeds clinical oncologist who led CR07, the trial that made short-course radiotherapy before surgery the standard for rectal cancer, and who now works on preserving the rectum instead of removing it.
David Sebag-Montefiore is an academic clinical oncologist at the University of Leeds and an honorary clinical oncologist at Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust. He leads the Leeds Radiotherapy Research Group and is a clinical director of the Leeds Clinical Trials Research Unit; he was awarded the Audrey and Stanley Burton Chair of Clinical Oncology in 2012. He was first author of MRC CR07, which showed that short-course preoperative radiotherapy cut local recurrence by 61 percent against surgery with selective postoperative chemoradiotherapy, and is second author of the STAR-TREC 12-month results, the first randomised comparison of two radiotherapy schedules for organ preservation in rectal cancer.
Shares Matt Seymour, Colorectal cancer and the tags colorectal, trialist, uk.
Shares Dion Morton, Matt Seymour, Leeds Cancer Centre, St James's University Hospital, Colorectal cancer and the tags colorectal, uk.
Shares Colorectal cancer and the tags colorectal, trialist, uk.
Shares Colorectal cancer and the tags colorectal, trialist, uk.
Shares Colorectal cancer and the tags colorectal, trialist, uk.
Shares Colorectal cancer and the tags colorectal, trialist.
Shares Rectal cancer, Colorectal cancer and the tags colorectal, uk.
Shares Rectal cancer, Colorectal cancer and the tags colorectal, uk.